Infant Bacterial Therapeutics AB (publ) (STO:IBT.B)
Sweden flag Sweden · Delayed Price · Currency is SEK
55.60
+1.90 (3.54%)
At close: May 22, 2026

STO:IBT.B Cash Flow Statement

Millions SEK. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
-71.36-65.17-136.91-123.07-65.45-44.99
Other Amortization
0.820.820.820.820.820.82
Stock-Based Compensation
0.410.24----
Other Operating Activities
-182.767.04-5.442.07-33-18.85
Change in Accounts Receivable
189.98-2.385.28-9.317.154.34
Change in Other Net Operating Assets
6.14-12.8923.1228.274.693.06
Operating Cash Flow
-56.78-72.34-113.13-101.22-85.8-55.62
Other Investing Activities
-----0.02-
Investing Cash Flow
-----0.02-
Issuance of Common Stock
---101.04--
Other Financing Activities
--2.01-4.521.90.09
Financing Cash Flow
--2.0196.521.90.09
Foreign Exchange Rate Adjustments
349.77.045.45-2.073318.85
Miscellaneous Cash Flow Adjustments
-352.75-14.09-00-0-
Net Cash Flow
-59.83-79.38-105.68-6.78-50.91-36.69
Free Cash Flow
-56.78-72.34-113.13-101.22-85.8-55.62
Free Cash Flow Margin
---2828325.00%-131453.25%-714958.33%-
Free Cash Flow Per Share
-4.21-5.37-8.40-8.19-7.64-4.96
Cash Interest Paid
----0.290.41
Levered Free Cash Flow
-35.52-57.33-61.62-64.36-28.66-19.96
Unlevered Free Cash Flow
-35.52-57.33-61.62-64.36-28.47-19.71
Change in Working Capital
196.12-15.2728.418.9611.847.4
Source: S&P Global Market Intelligence. Standard template. Financial Sources.